Rodent models for Alzheimer's disease drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 7, 2015, Pages 703-711

  Puzzo, Daniela ^a   Gulisano, Walter ^a   Palmeri, Agostino ^a   Arancio, Ottavio ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Aging; Alzheimer's disease; Behavior; Memory; Synaptic plasticity; Transgenic models

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BEHAVIOR; CLINICAL FEATURE; DRUG SCREENING; EXPERIMENTAL MODEL; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RODENT MODEL; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; GENETICS; HUMAN; MOUSE; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; RODENT; SPECIES DIFFERENCE;

AGING; ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, TRANSGENIC; RODENTIA; SPECIES SPECIFICITY;

EID: 84932088556     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1041913     Document Type: Review

References (89)

1. Alzheimer A. Über einen eigenartigen schweren Erkrankungsproze der Hirnrinde. Neurol Centralblatt 1906;23:1129-36
2. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet 1997;349:1546-9
3. Kraepelin E. Psychiatrie: Ein Lehrbuch für Studierende und Ärzte. Barth; Leipzig: 1910. p. 593-632
4. Rocca WA, Amaducci LA, Schoenberg BS. Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 1986;19:415-24
5. St George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000;47:183-99
6. Tang YP, Gershon ES. Genetic studies in Alzheimer's disease. Dialogues Clin Neurosci 2003;5:17-26
7. Xia D, Watanabe H, Wu B, et al. Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer's Disease. Neuron 2015;85:967-81
8. Quon D, Wang Y, Catalano R, et al. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 1991;352:239-41
9. Higgins LS, Holtzman DM, Rabin J, et al. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 1994;35:598-607
10. Sandhu FA, Salim M, Zain SB. Expression of the human beta-amyloid protein of Alzheimer's disease specifically in the brains of transgenic mice. J Biol Chem 1991;266:21331-4
11. Lamb BT, Sisodia SS, Lawler AM, et al. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat Genet 1993;5:22-30
12. Pearson BE, Choi TK. Expression of the human beta-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice. Proc Natl Acad Sci USA 1993;90:10578-82
13. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-7
14. Masliah E, Sisk A, Mallory M, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996;16:5795-811
15. Dodart JC, Meziane H, Mathis C, et al. Behavioral disturbances in transgenic mice overexpressing the V717F betaamyloid precursor protein. Behav Neurosci 1999;113:982-90
16. Chen G, Chen KS, Knox J, et al. A learning deficit related to age and betaamyloid plaques in a mouse model of Alzheimer's disease. Nature 2000;408:975-9
17. Gerlai R, Fitch T, Bales KR, et al. Behavioral impairment of APP(V717F) mice in fear conditioning: is it only cognition? Behav Brain Res 2002;136:503-9
18. Dodart JC, Mathis C, Saura J, et al. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiol Dis 2000;7:71-85
19. Reilly JF, Games D, Rydel RE, et al. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci USA 2003;100:4837-42
20. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102
21. Corcoran KA, Lu Y, Turner RS, et al. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem 2002;9:243-52
22. King DL, Arendash GW. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 2002;75:627-42
23. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999;2:271-6
24. Stern EA, Bacskai BJ, Hickey GA, et al. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci 2004;24:4535-40
25. Lalonde R, Lewis TL, Strazielle C, et al. Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res 2003;977:38-45
26. Gil-Bea FJ, Aisa B, Schliebs R, et al. Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav Neurosci 2007;121:340-4
27. Bedrosian TA, Herring KL, Weil ZM, et al. Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc Natl Acad Sci USA 2011;108:11686-91
28. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100
29. Trinchese F, Liu S, Battaglia F, et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004;55:801-14
30. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007;25:611-67
31. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-13
32. Herreman A, Hartmann D, Annaert W, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999;96:11872-7
33. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-13
34. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-45
35. Gong B, Vitolo OV, Trinchese F, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004;114:1624-34
36. Gong B, Cao Z, Zheng P, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006;126:775-88
37. Trinchese F, Fa' M, Liu S, et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 2008;118:2796-807
38. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloidbeta load in an Alzheimer's disease mouse model. J Neurosci 2009;29:8075-86
39. Perez-Gonzalez R, Pascual C, Antequera D, et al. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging 2013;34:2133-45
40. Zhang J, Guo J, Zhao X, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers betaamyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 2013;250:230-7
41. Liu MY, Wang S, Yao WF, et al. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. Neuroscience 2014;273:141-51
42. McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014;76:57-67
43. Sierksma AS, van den Hove DL, Pfau F, et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 2014;77:120-30
44. Zhang MY, Zheng CY, Zou MM, et al. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging 2014;35:2713-25
45. Li H, Ruberu K, Muñoz SS, et al. Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice. Neurobiol Aging 2015. [Epub ahead of print]
46. Schrott LM, Jackson K, Yi P, et al. Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 2015;12:22-31
47. Arendash GW, King DL, Gordon MN, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 2001;891:42-53
48. Lok K, Zhao H, Zhang C, et al. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease. J Neurol Sci 2013;335:145-54
49. Jensen MT, Mottin MD, Cracchiolo JR, et al. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005;130:667-84
50. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-21
51. Billings LM, Oddo S, Green KN, et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005;45:675-88
52. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2014;71:110-30
53. Stevens LM, Brown RE. Reference and working memory deficits in the 3xTg-AD mouse between 2 and 15-months of age: A cross-sectional study. Behav Brain Res 2015;278:496-505
54. Cantarella G, Di Benedetto G, Puzzo D, et al. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. Brain 2015;138:203-16
55. Gimenez-Llort L, Blázquez G, Cañete T, et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007;31:125-47
56. Pietropaolo S, Feldon J, Yee BK. Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease. Behav Neurosci 2008;122:733-47
57. Sterniczuk R, Antle MC, Laferla FM, et al. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res 2010;1348:149-55
58. Bertoni-Freddari C, Sensi SL, Giorgetti B, et al. Decreased presence of perforated synapses in a triple-transgenic mouse model of Alzheimer's disease. Rejuvenation Res 2008;11:309-13
59. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006;26:10129-40
60. Jawhar S, Trawicka A, Jenneckens C, et al. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Ab aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 2012;33:196.e29-40
61. Andorfer C, Kress Y, Espinoza M, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003;86:582-90
62. Ma QL, Zuo X, Yang F, et al. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 2013;288:4056-65
63. Castillo-Carranza DL, Gerson JE, Sengupta U, et al. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 2014;40:S97-111
64. Polydoro M, Acker CM, Duff K, et al. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009;29:10741-9
65. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, et al. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: functionbased and target-based discovery approaches. Int Rev Neurobiol 2007;82:277-96
66. Balducci C, Forloni G. In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. Curr Pharm Des 2014;20:2491-505
67. Puzzo D, Lee L, Palmeri A, et al. Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol 2014;88:450-67
68. Moe JG, Puzzo D, Chatterjee I, et al. Evaluation of the effect of extracellular tau oligomers on synaptic function. Society for Neurosciences; Washington DC, USA. 2008
69. Moe JG, Chatterjee I, Davidowitz EJ, et al. Modulation of synaptic function by extracellular tau enriched in oligomers. Alzheimers Dement 2009;5:P499
70. Moe JG, Chatterjee I, Puzzo D, et al. Validation of extracellular tau oligomer target for drug discovery in a novel animal model. Society for Neurosciences; San Diego, USA: 2010
71. Moe JG, Chatterjee I, Puzzo D, et al. Extracellular oligomeric tau inhibits memory formation in mice. Alzheimers Dement 2010;6:S277
72. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008;28:14537-45
73. Puzzo D, Privitera L, Fa' M, et al. Endogenous amyloid-b is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011;69:819-30
74. Puzzo D, Privitera L, Palmeri A. Hormetic effect of amyloid-b peptide in synaptic plasticity and memory. Neurobiol Aging 2012;33:1484.e15-24
75. Fiorito J, Saeed F, Zhang H, et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for thetreatment of Alzheimer's disease. Eur J Med Chem 2013;60:285-94
76. Watterson DM, Grum-Tokars VL, Roy SM, et al. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One 2013;8:e66226
77. Palmeri A, Privitera L, Giunta S, et al. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav Brain Res 2013;240:11-20
78. Puzzo D, Loreto C, Giunta S, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging 2014;35:520-31
79. Puzzo D, Bizzoca A, Loreto C, et al. Role of F3/contactin expression profile in synaptic plasticity and memory in aged mice. Neurobiol Aging 2015;36:1702-15
80. Takeda T, Hosokawa M, Takeshita S, et al. A new murine model of accelerated senescence. Mech Ageing Dev 1981;17:183-94
81. Treuting PM, Hopkins HC, Ware CA, et al. Generation of genetically altered mouse models for aging studies. Exp Mol Pathol 2002;72:49-55
82. Sprott RL. Introduction: animal models of aging: something old, something new. ILAR J 2011;52:1-3
83. Yeoman M, Scutt G, Faragher R. Insights into CNS ageing from animal models of senescence. Nat Rev Neurosci 2012;13:435-45
84. Li Q, Zhao HF, Zhang ZF, et al. Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience 2009;159:1208-15
85. Bergado JA, Almaguer W, Rojas Y, et al. Spatial and emotional memory in aged rats: a behavioral-statistical analysis. Neuroscience 2011;172:256-69
86. Wang W, Li S, Dong HP, et al. Differential impairment of spatial and nonspatial cognition in a mouse model of brain aging. Life Sci 2009;85:127-35
87. Soontornniyomkij V, Risbrough VB, Young JW, et al. Hippocampal calbindin-1 immunoreactivity correlate of recognition memory performance in aged mice. Neurosci Lett 2012;516:161-5
88. Placanica L, Zhu L, Li YM. Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One 2009;4:e5088
89. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91